DuoResp (R) Spiromax (R) adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT)-
Por:
van der Palen, J, Cerveri, I, Roche, N, Singh, D, Plaza, V, Gonzalez, C, Patino, O, Scheepstra, I, Safioti, G, Backer, V
Publicada:
2 oct 2020
Ahead of Print:
1 jul 2019
Resumen:
Objective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp (R) Spiromax (R) among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of inhaled corticosteroid (ICS) and long-acting beta(2)-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. DuoResp Spiromax users self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8 (R)), and ease of use and satisfaction using 10-point scales, during a single physician's office visit. Results: Of 1661 (asthma: n = 1101; COPD: n = 560) SPRINT study participants, 342 (asthma: n = 235; COPD: n = 107) received DuoResp Spiromax prior to inclusion. Overall, 72.5% of DuoResp Spiromax users reported medium or high adherence (MMAS-8 score >= 6). Mean (standard deviation [SD]) satisfaction score for DuoResp Spiromax was 8.9 (1.6). Almost all (98.8%) DuoResp Spiromax users were at least satisfied with their inhaler; 85.4% were very satisfied. Mean (SD) ease of use score for DuoResp Spiromax was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use.
Filiaciones:
van der Palen, J:
Univ Twente, Dept Res Methodol Measurement & Data Anal, Enschede, Netherlands
Med Spectrum Twente, Med Sch Twente, POB 50000, NL-7500 KA Enschede, Netherlands
Cerveri, I:
Univ Pavia, Unit Resp Dis, IRCCS Policlin San Matteo, Pavia, Italy
Roche, N:
Univ Paris 05, Hop Univ Paris Ctr, Cochin Hosp, AP HP,EA2511, Paris, France
Singh, D:
Univ Manchester, Ctr Resp Med & Allergy, Manchester, Lancs, England
Univ Hosp South Manchester NHS Fdn Trust, Med Evaluat Unit, Manchester, Lancs, England
Plaza, V:
Hosp Santa Creu & Sant Pau, IIB St Pau, Dept Resp Med & Allergy, Barcelona, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Gonzalez, C:
Experior SL, Unit Stat & Data Management, Valencia, Spain
Patino, O:
Teva Pharmaceut, Amsterdam, Netherlands
Scheepstra, I:
Teva Pharmaceut, Amsterdam, Netherlands
Safioti, G:
Teva Pharmaceut, Amsterdam, Netherlands
Backer, V:
Univ Copenhagen, Bispebjerg Univ Hosp, Dept Resp Med, Copenhagen, Denmark
|